Adam Waldman (Affiliate)

Imaging Biomarkers in Adult Glioma

A.Waldman
Professor Adam Waldman - Professor of Neuroradiology

Research in a Nutshell

The overall theme of my research is development and validation of quantitative and molecular imaging biomarkers which reflect key features of genetics and metabolism in human glioma, for clinical stratification, therapeutic planning and drug development:

Experimental phase MRI and PET imaging studies of intermediary metabolism, validated against tissue metabolic markers from defined tumour regions; for more reliable tumour characterisation, and identification of potential therapeutic targets.

Translational multi-centre platform studies of early therapeutic response in GBM using quantitative diffusion imaging for improved endpoints in clinical trials and clinical decision-making.

Quantitative MRI for treatment stratification and planning in adult supratentorial low grade glioma.

Development of PET-MRI methodology and co-analysis for improved glioma characterization.

Integration of quantitative MRI and PET into surgical neuro-navigation systems, for improved targeting for biopsy and surgical resection.

People

 
Adam WaldmanPrincipal Investigator and Professor of Neuroradiology
Gerard ThompsonSenior Lecturer in Neuroradiology
Antoine VallatosResearch Associate in Preclinical and Clinical Brain Imaging
Matt Grech-SollarsPost Doctoral RA (based at Imperial College, London)
Shah IslamClinical Research Fellow (based at Imperial College, London)
Melanie MorrisonPost Doctoral RA (based at Imperial College, London)

Contact

Adam.Waldman@ed.ac.uk

 

Collaborations

  • Dr Steve Pollard, University of Edinburgh 
  • Professor Anthony Chalmers, University of Glasgow
  • Professor Eric Aboagye, Imperial College London
  • Professor Catharina Svanborg, University of Lund

Partners and Funders

  • The Brain Tumour Charity
  • Brain Tumour Research Campaign

Scientific Themes

Imaging of glioma genetics and metabolism, drug distribution and pharmacodynamics; non-invasive markers of progression, invasion and therapeutic response

Technology Expertise

Quantitative and molecular neuroimaging; predominantly quantitative MRI and PET

This article was published on